Alembic Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹2,603 crore and net profit of ₹334 crore for the September 2026 quarter.
Alembic Pharmaceuticals (NSE: APLLTD) closed at ₹1,040.95 on 20 Nov 2026, up 15.7% over the past year. Its market capitalisation is ₹20,461 crore and it trades at 22.8 times earnings.
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.